Protective and Anti-Pathology Effects of Sm Fructose-1,6- Bisphosphate Aldolase-Based DNA Vaccine against Schistosoma mansoni by Changing Route of Injection
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
This study aimed to evaluate the efficacy of fructose-1,6-bis phosphate aldolase (SMALDO) DNA vaccination against Schistosoma mansoni infection using different routes of injection. The SMALDO has been cloned into the eukaryotic expression vector pcDNA3.1/V5-His TOPO-TA and was used in injecting Swiss albino mice intramuscularly (IM), subcutaneously (SC), or intraperitoneally (IP) (50 μg/mouse). Mice vaccinated with non-recombinant pcDNA3.1 served as controls. Each group was immunized 4 times at weeks 0, 2, 4, and 6. Two weeks after the last booster dose, all mice groups were infected with 80 S. mansoni cercariae via tail immersion. At week 8 post-infection, animals were sacrificed for assessment of parasitological and histopathological parameters. High anti-SMALDO IgG antibody titers were detected in sera of all vaccinated groups (P<0.01) compared to the control group. Both the IP and SC vaccination routes resulted in a significant reduction in worm burden (46.2% and 28.9%, respectively, P<0.01). This was accompanied by a significant reduction in hepatic and intestinal egg counts (41.7% and 40.2%, respectively, P<0.01) in the IP group only. The number of dead eggs was significantly increased in both IP and IM groups (P<0.01). IP vaccination recorded the highest significant reduction in granuloma number and diameter (54.7% and 29.2%, respectively, P<0.01) and significant increase in dead miracidia (P<0.01). In conclusion, changing the injection route of SMALDO DNA vaccination significantly influenced the efficacy of vaccination. SMALDO DNA vaccination via IP route could be a promising protective and antipathology vaccine candidate against S. mansoni infection.
Abstract
This study aimed to evaluate the efficacy of fructose-1,6-bis phosphate aldolase (SMALDO) DNA vaccination against Schistosoma mansoni infection using different routes of injection. The SMALDO has been cloned into the eukaryotic expression vector pcDNA3.1/V5-His TOPO-TA and was used in injecting Swiss albino mice intramuscularly (IM), subcutaneously (SC), or intraperitoneally (IP) (50 μg/mouse). Mice vaccinated with non-recombinant pcDNA3.1 served as controls. Each group was immunized 4 times at weeks 0, 2, 4, and 6. Two weeks after the last booster dose, all mice groups were infected with 80 S. mansoni cercariae via tail immersion. At week 8 post-infection, animals were sacrificed for assessment of parasitological and histopathological parameters. High anti-SMALDO IgG antibody titers were detected in sera of all vaccinated groups (P<0.01) compared to the control group. Both the IP and SC vaccination routes resulted in a significant reduction in worm burden (46.2% and 28.9%, respectively, P<0.01). This was accompanied by a significant reduction in hepatic and intestinal egg counts (41.7% and 40.2%, respectively, P<0.01) in the IP group only. The number of dead eggs was significantly increased in both IP and IM groups (P<0.01). IP vaccination recorded the highest significant reduction in granuloma number and diameter (54.7% and 29.2%, respectively, P<0.01) and significant increase in dead miracidia (P<0.01). In conclusion, changing the injection route of SMALDO DNA vaccination significantly influenced the efficacy of vaccination. SMALDO DNA vaccination via IP route could be a promising protective and antipathology vaccine candidate against S. mansoni infection.
참고문헌 (35)
- El-Khoby T, "The epidemiology of schistosomiasis in Egypt: summary findings in nine governorates", Am J Trop Med Hyg, 62, pp.88~99 (2000)
- McManus DP, "Current status of vaccines for schistosomiasis", Clin Microbiol Rev, 21, pp.225~242 (2008)
- Richter D, "Candidate vaccine antigens that stimulate the cellular immune response of mice vaccinated with irradiated cercariae of Schistosoma mansoni", J Immunol, 151, pp.256~265 (1993)
- El-Dabaa E, "Cloning and characterization of Schistosoma mansoni fructose-1,6-bisphosphate aldolase isozyme", J Parasitol, 84, pp.954~960 (1998)
- Skelly PJ, "Expression of Schistosoma mansoni genes involved in anaerobic and oxidative glucose metabolism during the cercariae to adult transformation", Molecular Biochem Parasitol, 60, pp.93~104 (1993)
- Mathews CK, "Biochemistry", pp.1990, The Bengamin
- Rumjanek FK, "Biochemistry and physiology, In The Biology of Schistosomes", pp.163~183 (1987), Academic Press
- Harrop R, "Characterization, cloning and immunogenicity of antigens released by lung-stage larvae of Schistosoma msnoni", Parasitology, 118, pp.583~594 (1999)
- Marques HH, "Protective effect and granuloma down-modulation promoted by RP44 antigen a fructose 1,6 bisphosphate aldolase of Schistosoma mansoni", Immunobiology, 213, pp.437~446 (2008)
- Capron A, "Prospects for a schistosome vaccine", Curr Drug Targets Immune Endocr Metabol Disord, 2, pp.281~290 (2002)
- Melkebeek V, "Optimized FaeG expression and a thermolabile enterotoxin DNA adjuvant enhance priming of an intestinal immune response by an FaeG DNA vaccine in pigs", Clin Vaccine Immunol, 14, pp.28~35 (2007)
- Wei F, "IL-18 enhances protective effect in mice immunized with a Schistosoma japonicum FABP DNA vaccine", Acta Trop, 3, pp.284~288 (2009)
- Zhu Y, "Synergistic enhancement of immunogenicity and protection in mice against Schistosoma japonicum with codon optimization and electroporation delivery of SjTPI DNA vaccines", Vaccine, 28, pp.5347~5355 (2010)
- Ahmed H, "DNA Immunization with the gene encoding Sm21.7 protein protects mice against Schistosoma mansoni infections", J Am Sci, 2, pp.59~69 (2006)
- Romeih MH, "Immunization against Egyptian Schistosoma mansoni infection by multivalent DNA vaccine", Acta Biochim Biophys Sin (Shanghai), 40, pp.327~338 (2008)
- Nessim N, "Effect of the broad spectrum antihelmintic drug flubendazole upon Schistosoma mansoni experimentally infected mice", Arzneimittelforschung, 50, pp.1129~1113 (2000)
- Innis MA, "PCR Protocols. A Guide to Methods and Applications", pp.4~36 (1990), Academic Press
- Shuman S, "Novel approach to molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase", J Biol Chem, 269, pp.32678~32684 (1994)
- Sambrook J, "Molecular Cloning: A Laboratory Manual" (2001), Cold Spring Harbor Laboratory Press
- Shalaby KA, "Protection against Schistosoma mansoni utilizing DNA vaccination with genes encoding Cu", Zn cytosolic superoxide dismutase, signal peptide-containing superoxide dismutase and glutathione peroxidase enzymes, 2003, pp.22, 130~136
- Hillyer GV, "The enzyme-linked immunosorbent assay (ELISA) for the immunodiagnosis of schistosomiasis", Am J Trop Med Hyg, 28, pp.237~241 (1979)
- Duvall R, "An improved perfusion technique for recovering adult schistosomes from laboratory animals", Am J Trop Med Hyg, 6, pp.483~486 (1967)
- Kamel I, "Schistosoma mansoni and Schistosoma haematobium infections in Egypt. I. Evaluation of techniques for recovery of worms and eggs at necropsy", Am J Trop Med Hyg, 26, pp.696~701 (1977)
- Pellegrino J, "New approach to the screening of drugs in experimental schistosomiasis mansoni in mice", Am J Trop Med Hyg, 11, pp.201~215 (1962)
- von Lichtenberg FC, "Host response to eggs of Schistosoma mansoni. I. Granuloma formation in the sensitized laboratory mouse", Am J Pathol, 41, pp.711~731 (1962)
- Coban C, "Novel strategies to improve DNA vaccine immunogenicity", Curr Gene Ther, 11, pp.479~484 (2011)
- Kozak M, "An analysis of 5´-noncoding sequences from 699 vertebrate messenger RNAs", Nucleic Acids Res, 15, pp.8125~8148 (1987)
- Cherif MS, "Immunogenicity of novel nanoparticle-coated MSP-1 C-terminus malaria DNA vaccine using different routes of administration", Vaccine, 29, pp.9038~9050 (2011)
- Kedzierska K, "Induction of protective CD4+ T cell-mediated immunity by a Leishmania peptide delivered in recombinant in fluenza viruses", PLoS One, 7, pp.e33161~ (2012)
- Lundstrom K, "Alphavirus-based vaccines", Curr Opin Mol Ther, 4, pp.28~34 (2002)
- Zhu Y, "The protective effect of a Schistosoma japonicum Chinese strain 23 kDa plasmid DNA vaccine in pigs is enhanced with IL-12", Vaccine, 23, pp.78~83 (2004)
- Wynn TA, "An IL-12 based vaccination method for preventing fibrosis induced by schistosome infection", Nature, 376, pp.594~596 (1995)
- Hoffmann KF, "INF-gamma, IL- 12 and TNF-alpha are required to maintain reduced liver pathology in mice vaccinated with Schistosoma mansoni eggs and IL-12", J Immunol, 161, pp.4201~4210 (1998)
- Pearce EJ, "IL-4 in schistosomiasis", Exp Parasitol, 84, pp.295~299 (1996)
- Eberl M, "IL-18 potentiates the adjuvant properties of IL-12 in the induction of a strong Th1 type immune response against a recombinant antigen", Vaccine, 18, pp.2002~2008 (2000)